The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
The MDM2-p53 pathway revisited
Open accessAbstract
The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better understand the pathway and exploit it for anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 2×
“MDM2 targets p53 for ubiquitination and degradation by the proteasome([69-71]), shuttles p53 out of the nucleus([69,70]), prevents p53 from interacting with transcriptional co-activators([72]), and recruits transcriptional co-repressors to p53([73-75]).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…taken to develop small molecule MDM2 inhibitors, with most efforts focused on the development of agents designed to inhibit the interaction between MDM2 and p53 (e.g. Nutlins, spiro-oxindoles, benzodiazepines and RITA-reactivation of p53 and induction of tumor cell apoptosis)[13,27,141,143-145].”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 2×
“In addition, the C-terminal RING finger domain MDM2 serves as an E3 ubiquitin ligase for p53 proteolysis and ubiquitinates p53 at several lysine residues([77-82]).”
BackgroundMDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Mayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,031
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 780
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 731 · cited 1×
“Another facet of MDM2 regulation involves posttranslational modifications([43]) including phosphorylation of the MDM2 protein by upstream molecules such as ATM (decreases MDM2 stability)([43-45]) and Akt (increases MDM2 translocation from the cytoplasm into the nucleus, allowing p53 degradation)([46-49]).”
BackgroundAssociation of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., & Gotoh, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109745200 · Cited by 617 · cited 1×
“Another facet of MDM2 regulation involves posttranslational modifications([43]) including phosphorylation of the MDM2 protein by upstream molecules such as ATM (decreases MDM2 stability)([43-45]) and Akt (increases MDM2 translocation from the cytoplasm into the nucleus, allowing p53 degradation)([46-49]).”
BackgroundSignaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580
The expanding universe of p53 targets
Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568
Zhang, Y., Wolf, G. W., Bhat, K., Jin, A., Allio, T., Burkhart, W. A., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8902-8912.2003 · Cited by 558
Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5
Dai, M.-S., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403722200 · Cited by 534
(1994) · PubMed · Cited by 509
Dai, M.-S., Zeng, S. X., Jin, Y., Sun, X.-X., David, L., & Lu, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7654-7668.2004 · Cited by 489
Wild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 435
Yin Yang 1 Is a Negative Regulator of p53
Sui, G., Affar, E. B., Shi, Y., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P., Calvo, D., Grossman, S. R., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.004 · Cited by 424
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · cited 9×
“MDMX also directly binds to the transactivation domain of p53 and inhibits p53 activity, but does not induce p53 degradation.”
BackgroundInfluentialMultiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., & Hay, R. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8458-8467.2000 · Cited by 389
Opposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Cahilly-Snyder, L., Yang-Feng, T., Francke, U., & George, D. L. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535205 · Cited by 355
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 322
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 292
The multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287
Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202515 · Cited by 279
Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex
Weber, J. D., Kuo, M.-L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., & Sherr, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2517-2528.2000 · Cited by 275
Repression of p53-mediated transcription by MDM2: a dual mechanism
Thut, C. J., Goodrich, J. A., & Tjian, R. (1997) · Genes & Development · doi:10.1101/gad.11.15.1974 · Cited by 272
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Self-citationZhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., & Pollock, R. E. (2000) · PubMed · Cited by 263
Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E. R., Hill, D. L., Wang, H., & Zhang, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210327 · Cited by 261
RB Regulates the Stability and the Apoptotic Function of p53 via MDM2
Hsieh, J.-K., Chan, F. S. G., O’Connor, D. J., Mittnacht, S., Zhong, S., & Lu, X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80309-3 · Cited by 255
MDM2 Is a Negative Regulator of p21 , Independent of p53
Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., & Zhang, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312264200 · Cited by 252
14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth
Yang, H.-Y., Wen, Y.-Y., Chen, C.-H., Lozano, G., & Lee, M.-H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7096-7107.2003 · Cited by 229
The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53
Higashitsuji, H., Higashitsuji, H., Itoh, K., Sakurai, T., Nagao, T., Sumitomo, H., Masuda, T., Dawson, S., Shimada, Y., Mayer, R. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.006 · Cited by 228
Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.-G., & Chen, W.-T. (2013) · Oncogene · doi:10.1038/onc.2012.28 · Cited by 224
Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2
Zhu, Y., Poyurovsky, M. V., Li, Y., Biderman, L., Stahl, J., Jacq, X., & Prives, C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.014 · Cited by 206
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation
Fu, W., Ma, Q., Chen, L., Li, P., Zhang, M., Ramamoorthy, S., Nawaz, Z., Shimojima, T., Wang, H., Yang, Y., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901758200 · Cited by 201
Nakamura, S., Roth, J. A., & Mukhopadhyay, T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9391-9398.2000 · Cited by 199
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain
Popowicz, G., Czarna, A., & Holak, T. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 194
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 190
HAUSP is Required for p53 Destabilization
Cummins, J. M., & Vogelstein, B. (2004) · Cell Cycle · doi:10.4161/cc.3.6.924 · Cited by 189
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 189
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
Olson, D. C., Maréchal, V., Momand, J. A., Chen, J., Romocki, C., & Levine, A. J. (1993) · PubMed · Cited by 188
Mdmx as an essential regulator of p53 activity
Marine, J.-C., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 188
Enhanced Mdm2 activity inhibits pRB function via ubiquitin‐dependent degradation
Uchida, C., Miwa, S., Kitagawa, K., Hattori, T., Isobe, T., Otani, S., Oda, T., Sugimura, H., Kamijo, T., Ookawa, K., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600486 · Cited by 184
Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop
Oliver, T. G., Meylan, E., Chang, G. P., Xue, W., Burke, J. R., Humpton, T. J., Hubbard, D., Bhutkar, A. J., & Jacks, T. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.012 · Cited by 181
Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2
Linares, L. K., Kiernan, R., Triboulet, R., Chable-Bessia, C., Latreille, D., Cuvier, O., Lacroix, M., Le Cam, L., Coux, O., & Benkirane, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1545 · Cited by 180
Regulation of XIAP Translation and Induction by MDM2 following Irradiation
Gu, L., Zhu, N., Zhang, H., Durden, D. L., Feng, Y., & Zhou, M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.002 · Cited by 178
Ribosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress
Zhou, X., Hao, Q., Liao, J., Zhang, Q., & Lu, H. (2013) · Oncogene · doi:10.1038/onc.2012.63 · Cited by 176
Rinaldo, C., Prodosmo, A., Mancini, F., Iacovelli, S., Sacchi, A., Moretti, F., & Soddu, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.008 · Cited by 174
Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P. A., Copeland, R. A., & Auger, K. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011517200 · Cited by 167
ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation
Meulmeester, E., Pereg, Y., Shiloh, Y., & Jochemsen, A. G. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1981 · Cited by 167
Xiong, X., Zhao, Y., He, H., & Sun, Y. (2010) · Oncogene · doi:10.1038/onc.2010.569 · Cited by 158
The C terminus of p53 binds the N-terminal domain of MDM2
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 157
Proteasome activator PA28γ regulates p53 by enhancing its MDM2‐mediated degradation
Zhang, Z., & Zhang, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.25 · Cited by 156
Structural Details on mdm2-p53 Interaction
Chi, S., Lee, S., Kim, D., Ahn, M.-J., Js, K., Woo, J.-Y., Torizawa, T., Kainosho, M., & Han, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508578200 · Cited by 152
Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 141
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 140
The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation
Louria‐Hayon, I., Grossman, T., Sionov, R. V., Alsheich-Bartok, O., Pandolfi, P. P., & Haupt, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301264200 · Cited by 137
Mdm2 and MdmX partner to regulate p53
Wang, X., & Jiang, X. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.049 · Cited by 135
Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair
Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413387200 · Cited by 131
Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131
Thomasová, D., Mulay, S. R., Bruns, H., & Anders, H. (2012) · Neoplasia · doi:10.1593/neo.121534 · Cited by 129
The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression
Dar, A. A., Majid, S., Rittsteuer, C., de Semir, D., Bezrookove, V., Tong, S., Nosrati, M., Sagebiel, R. W., Miller, J. R., & Kashani–Sabet, M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt003 · Cited by 122
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
Chappell, W. H., Lehmann, B. D., Terrian, D. M., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22852 · Cited by 118
Identification of ribosomal protein S25 (RPS25)–MDM2–p53 regulatory feedback loop
Zhang, X., Wang, W., Wang, H., Wang, M.-H., Xu, W., & Zhang, R. (2012) · Oncogene · doi:10.1038/onc.2012.289 · Cited by 117
Bitomsky, N., & Hofmann, T. G. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07331.x · Cited by 116
MDM2 Oncogene as a Novel Target for Human Cancer Therapy
Zhang, R., & Wang, H. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400911 · Cited by 113
MDM2 SNP309 and cancer risk: a combined analysis
Wilkening, S., Bermejo, J. L., & Hemminki, K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm191 · Cited by 109
Ray, R. M., Bhattacharya, S., & Johnson, L. R. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0538-0 · Cited by 108
Ribosomal protein S27L is a direct p53 target that regulates apoptosis
He, H., & Sun, Y. (2006) · Oncogene · doi:10.1038/sj.onc.1210073 · Cited by 108
p53-Dependent and -Independent Functions of the Arf Tumor SuppressorPreprint
Sherr, C. J., Bertwistle, D., den Besten, W., KUO, M.-L., SUGIMOTO, M., Tago, K., Williams, R. T., Zindy, F., & Roussel, M. F. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.004 · Cited by 107
Mdm2 Promotes Genetic Instability and Transformation Independent of p53
Bouska, A., Lushnikova, T., Plaza, S., & Eischen, C. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01584-07 · Cited by 105
Single-nucleotide Polymorphisms in the p53 Signaling PathwayPreprint
Grochola, L. F., Zeron-Medina, J., Meriaux, S., & Bond, G. L. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001032 · Cited by 105
A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2
Boyd, M. T., Vlatković, N., & Haines, D. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004252200 · Cited by 96
Mdmx and Mdm2: Brothers in Arms?
Marine, J., & Jochemsen, A. G. (2004) · Cell Cycle · doi:10.4161/cc.3.7.998 · Cited by 95
RYBP stabilizes p53 by modulating MDM2
Chen, D., Zhang, J., Li, M., Rayburn, E. R., Wang, H., & Zhang, R. (2008) · EMBO Reports · doi:10.1038/embor.2008.231 · Cited by 89
Roles for CSN5 in control of p53/MDM2 activities
Zhang, X., Chen, J., Su, C., Yang, H.-Y., & Lee, M. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21504 · Cited by 88
Su, W., Fang, J., Cheng, F., Liu, C., Zhou, F., & Zhang, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211604110 · Cited by 87
Updates on HIPK2: a resourceful oncosuppressor for clearing cancer
D’Orazi, G., Rinaldo, C., & Soddu, S. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-63 · Cited by 86
Overexpression of the MDM2 Oncogene in Leukemia and Lymphoma
Watanabe, T., Ichikawa, A., Saito, H., & Hotta, T. (1996) · Leukemia & Lymphoma · doi:10.3109/10428199609093436 · Cited by 80
Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., & Liu, Z. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00084-8 · Cited by 80
MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
Mc, D.-P., Tocqué, B., & Wasylyk, B. (1995) · PubMed · Cited by 80
Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B. L., Tollenaar, R. A. �. �., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0738 · Cited by 79
p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53
Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 74
Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53
Kim, H., Kwak, N., Lee, J., Choi, B. H., Lim, Y., Ko, Y. J., Kim, Y.-H., Huh, P., Lee, K.-H., Rha, H. K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305526200 · Cited by 74
Mdm2 targets the p53 transcription cofactor JMY for degradation
Coutts, A., Boulahbel, H., Graham, A., & Thangue, N. L. (2007) · EMBO Reports · doi:10.1038/sj.embor.7400855 · Cited by 73
PML enhances the regulation of p53 by CK1 in response to DNA damage
Alsheich-Bartok, O., Haupt, S., Snir-Alkalay, I., Saito, S., Appella, E., & Haupt, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211036 · Cited by 71
Yu, H., Zou, Y., Jiang, L., Yin, Q., He, X., Chen, L., Zhang, Z., Gu, W., & Li, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.042 · Cited by 71
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 70
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 70
de Toledo, S. M., Azzam, E. I., Dahlberg, W. K., Gooding, T. B., & Little, J. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204020 · Cited by 67
Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73
Zdzalik, M., Pustelny, K., Kędracka–Krok, S., Huben, K., Pęcak, A., Władyka, B., Jankowski, S., Dubin, A., Potempa, J., & Dubin, G. (2010) · Cell Cycle · doi:10.4161/cc.9.22.13871 · Cited by 66
Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability
Wen, W., Peng, C., Kim, M., Jeong, C. H., Zhu, F., Yao, K., Zykova, T. A., Ma, W., Carper, A., Langfald, A., et al. (2013) · Oncogene · doi:10.1038/onc.2012.605 · Cited by 66
The p53/microRNA Network in Cancer: Experimental and Bioinformatics Approaches
Hünten, S., Siemens, H., Kaller, M., & Hermeking, H. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_5 · Cited by 66
Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53
Zhang, X., Zhang, Z., Cheng, J., Li, M., Wang, W., Xu, W., Wang, H., & Zhang, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373738 · Cited by 65
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)
Żak, K. M., Pęcak, A., Ryś, B., Władyka, B., Dömling, A. S. S., Weber, L., Holak, T. A., & Dubin, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.765405 · Cited by 65
Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53
Wang, L., He, G., Zhang, P., Wang, X., Jiang, M. H., & Yu, L. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0099-x · Cited by 62
Zhang, R., Wang, H., & Agrawal, S. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332663 · Cited by 61
Mammalian Numb is a target protein of Mdm2, ubiquitin ligase
Yogosawa, S., Miyauchi, Y., Honda, R., Tanaka, H., & Yasuda, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00282-1 · Cited by 59
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 58
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination
Maguire, M., Nield, P. C., Devling, T., Jenkins, R. E., Park, B. K., Polański, R., Vlatković, N., & Boyd, M. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5271 · Cited by 57
Prodosmo, A., Giglio, S., Moretti, S., Mancini, F., Barbi, F., Avenia, N., Conza, G. D., Schünemann, H. J., Pistola, L., Ludovini, V., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0322-6 · Cited by 57
Lauria, A., Tutone, M., Ippolito, M., Pantano, L., & Almerico, A. M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710792232021 · Cited by 56
Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction
Rothweiler, U., Czarna, A., Krajewski, M., Ciombor, J., Kalinski, C., Khazak, V., Roß, G., Skobeleva, N., Weber, L., & Holak, T. A. (2008) · ChemMedChem · doi:10.1002/cmdc.200800025 · Cited by 55
Zhang, Z., Wang, H., Prasad, G., Li, M., Yu, D. S., Bonner, J. A., Agrawal, S., & Zhang, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0245-03 · Cited by 55
p53 regulation: Teamwork between RING domains of Mdm2 and MdmX
Wang, X. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18662 · Cited by 54
Volpe, J. P. G. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90179-3 · Cited by 53
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Wan, Y., Wu, W., Yin, Z., Guan, P., & Zhou, B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-208 · Cited by 52
Nucleostemin: Another nucleolar "Twister" of the p53-MDM2 loop
Lo, D., & Lu, H. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12605 · Cited by 52
Xiong, L., Kou, F., Yang, Y., & Wu, J. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703044 · Cited by 51
Tang, Y.-A., Lin, R.-K., Tsai, Y.-T., Hsu, H., Yang, Y., Chen, C., & Wang, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2617 · Cited by 51
Recent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 50
Gama, V, Gomez, J. A., Mayo, L. D., Jackson, M. W., Danielpour, D., Song, K., Haas, A. L., Laughlin, M. J., & Matsuyama, S. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.6 · Cited by 46
MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase varepsilon
Vlatković, N., Guerrera, S., Li, Y., Linn, S., Haines, D. S., & Boyd, M. T. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.18.3581 · Cited by 44
Specific inhibition of Mdm2-mediated neddylation by Tip60
Dohmesen, C., Koeppel, M., & Dobbelstein, M. (2008) · Cell Cycle · doi:10.4161/cc.7.2.5185 · Cited by 43
MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change
Xu, H., Zhang, Z., Li, M., & Zhang, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059568 · Cited by 42
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization
Xu, G. W., Mawji, I. A., Macrae, C. J., Koch, C. A., Datti, A., Wrana, J. L., Dennis, J. W., & Schimmer, A. D. (2008) · APOPTOSIS · doi:10.1007/s10495-007-0175-4 · Cited by 41
Park, E. J., Choi, K. S., Yoo, Y. H., & Kwon, T. K. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835c0311 · Cited by 38
ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 37
Direct transcriptional regulation of MDM2 by Fli-1
Truong, A. H. L., Cervi, D. N., Lee, J., & Ben‐David, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1208323 · Cited by 34
Nutlin‐3 enhances sorafenib efficacy in renal cell carcinoma
Vatsyayan, R., Singhal, J., Nagaprashantha, L. D., Awasthi, S., & Singhal, S. S. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20875 · Cited by 34
Stimulation of human DNA polymerase epsilon by MDM2
Asahara, H. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg342 · Cited by 33
Kenjo, E., Asai, T., Yonenaga, N., Ando, H., Ishii, T., Hatanaka, K., Shimizu, K., Urita, Y., Dewa, T., Nango, M., et al. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00817 · Cited by 33
p53–Mdm2 inhibitors: patent review (2009 – 2010)
Kamal, Ä., Mohammed, A. A., & Shaik, T. B. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.656593 · Cited by 30
Brown, C. J., Dastidar, S. G., See, H. Y., Coomber, D., Ortiz-Lombardı́a, M., Verma, C. S., & Lane, D. P. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.069 · Cited by 25
A novel oncoprotein Pirh2: rising from the shadow of MDM2
Wang, Z., Yang, B. R., Dong, L., Peng, B., He, X., & Liu, W. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01899.x · Cited by 24
Malaguarnera, R., Vella, V., Pandini, G., Sanfilippo, M., PEZZINO, V., Vigneri, R., & Frasca, F. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0005 · Cited by 24
Novel MDM2 p53‐Independent Functions Identified through RNA Silencing Technologies
Zhang, Z., Wang, H., Li, M., Rayburn, E. R., Agrawal, S., & Zhang, R. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1359.030 · Cited by 22
Schilling, D., Düwel, M., Molls, M., & Multhoff, G. (2012) · Cell Stress and Chaperones · doi:10.1007/s12192-012-0369-8 · Cited by 19
Oncogenes as Novel Targets for Cancer Therapy (Part II): Intermediate Signaling Molecules
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505040-00005 · Cited by 14
Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
den Besten, W., Kuo, M., Tago, K., Williams, R. T., & Sherr, C. J. (2006) · PubMed · Cited by 14
Oncogenes as Novel Targets for Cancer Therapy (Part III): Transcription Factors
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505050-00005 · Cited by 12
Cited by
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Quantitative Proteomics of the Cancer Cell Line Encyclopedia
Nusinow, D. P., Szpyt, J., Ghandi, M., Rose, C. M., McDonald, E. R., Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D. K., Jedrychowski, M., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.023 · Cited by 957
Mustafa, M., Ahmad, R., Tantry, I. Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin, Hassan, M. I., Habib, S., et al. (2024) · Cells · doi:10.3390/cells13221838 · Cited by 595
Kobayashi, Y., Tata, A., Konkimalla, A., Katsura, H., Lee, R. F., Ou, J., Banovich, N. E., Kropski, J. A., & Tata, P. R. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0542-8 · Cited by 559
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., Sakellaropoulos, T., Gong, Y., Kloetgen, A., Yap, Y. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0117 · Cited by 348
Metadata
- Authors
- Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z.
- Venue
- The Journal of Biomedical Research
- Publisher
- Journal of Biomedical Research
- Published
- 2013
- Volume
- 27
- Issue
- 4
- Pages
- 254
- ISSN
- 1674-8301 (ISSN-L)
- OpenAlex
- W2129062251
- Cited by
- 414
- References
- 162
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.